Category: Today’s Highlights

GlaxoSmithKline and Vir Biotechnology Announce Joint Procurement Agreement with the EC for COVID-19 Treatment  

GlaxoSmithKline and Vir Biotechnology Signed a Joint Procurement Agreement with the EC GlaxoSmithKline ( GSK ) and Vir Biotechnology ( VIR ) informed today the signing of a  Joint Procurement Agreement with the European Commission ( EC ) to supply up...

Read More

July 28, 2021

0

Sanofi to Acquire Translate Bio, Advancing mRNA Technology. See Also: Cassava Science Q2 Financial Results

Sanofi Will Acquire Translate Bio Sanofi ( SNY ) will acquire all the outstanding shares of  Translate Bio ( TBIO )  for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and...

Read More

August 3, 2021

0

Ionis Pharmaceuticals Announces that Pfizer Reported Positive Results of Vupanorsen for Cardiovascular Risk Reduction and Severe Hypertriglyceridemia

Ionis Pharmaceuticals Announced Pfizer Update of Vupanorsen Ionis Pharmaceuticals ( IONS ) announced that Pfizer's ( PFE ) update of the Phase 2b study of vupanorsen met its primary endpoin, achieving a statistically significant reduction in non-HDL-C at all doses tested...

Read More

November 25, 2021

0

The Omicron Variant and the Bizarre Stock Market Chaos

The Bizarre Assessment of Biotech Firms in the Stock Market The Clinical-Stage Biotechnology Firms  We are witnessing inexplicable evaluations of clinical-stage biotechnology companies. Bizarre is the best description of this group’s assessment which is based on incomes that do not...

Read More

November 30, 2021

0

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences ( GILD ) is in receipt of a complete response letter ( CRL ) from the U.S. Food and Drug Administration ( FDA ) for the New...

Read More

August 19, 2020

0

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181...

Read More

August 9, 2021

0

Great News: Vertex Pharmaceuticals Announced Successful Phase 2 Study Results of VX-147

Vertex Pharmaceuticals Phase 2 Results of VX-147 Vertex Pharmaceuticals ( VRTX ) announced today that, in a Phase 2 proof-of-concept ( POC ) study in patients with APOL1-mediated focal segmental glomerulosclerosis ( FSGS ), VX-147, on top of standard of...

Read More

December 1, 2021

0

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis ( EXEL ) announced the submission of a supplemental New Drug Application ( sNDA ) to the U.S. FDA for CABOMETYX® ( cabozantinib ) in combination with Opdivo® (nivolumab)...

Read More

August 25, 2020

0

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

GlaxoSmithKline and Vir Biotechnology Sotrovimab Retains In Vitro Activity Against Omicron GlaxoSmithKline plc ( GSK ) and  Vir Biotechnology ( VIR ) announced an update to preclinical data on bioRxiv1 - a preprint server, demonstrating that sotrovimab - an investigational monoclonal antibody,...

Read More

December 7, 2021

0

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis

Celldex Therapeutics Dosed the First Patient with CDX-0159 for Prurigo Nodularis Celldex Therapeutics ( CLDX ) announced that the first patient in a Phase 1 study of CDX-0159 for prurigo nodularis ( PN ) has been already dosed.  From Celldex...

Read More

December 8, 2021

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0